EUVIMEDEUVIMED entdecken
Open Access

Antihypertensive Drug Amlodipine Besylate Shows Potential in Alleviating Diabetic Peripheral Neuropathy

Yuxi Wei, Yujie Huang, Runzhi Huang, Yuan Ruan, Tian Feng, Fan Zhou, Wei Zhang, Jianyu Lu, Sujie Xie, Yuntao Yao, Jiaying Wang iD, Shizhao Ji iD und 1 weitere

Diabetes · 01.06.2025 · 74 (6) · 983-997

DOI: 10.2337/db24-0403 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, online erschienen am 28.02.2025. Verfasst von Yuxi Wei und 12 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Drug Target and Drug for Degenerative Diseases, School of Medicine, Nanjing University of Chinese Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Amlodipine, Diabetic Neuropathies, Antihypertensive Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Qinglan Project of Jiangsu Province of China, Innovation Projects of State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic peripheral neuropathy (DPN) is a common diabetes complication with no currently available curative treatments. Here, we demonstrated that the protein level of G-protein–coupled receptor 40 (GPR40) is significantly repressed in the sciatic nerves (SNs) of DPN patients, as well as in the peripheral nerves, including dorsal root ganglia (DRG) and SNs, of streptozotocin-induced type 1 diabetic mice and BKS Cg-m+/+Lepr db/J (db/db) type 2 diabetic mice. We identified that amlodipine besylate (AB), a first-line clinical antihypertensive drug, is a GPR40 agonist capable of alleviating DPN-like pathologies in mice. These pathologies include neurological damage, destruction of myelin sheath structures, vascular injury, loss of intraepidermal nerve fibers, and impaired neurite outgrowth in DRG neurons. To elucidate the underlying mechanisms, we generated the DPN mice with GPR40-specific knockdown in SN and DRG tissues using adeno-associated virus 8-GPR40-RNAi. Mechanistically, AB attenuated inflammatory responses via the GPR40/β-arrestin2/NLRP3 pathway and ameliorated mitochondrial dysfunction through the GPR40/LKB1/AMPK/SIRT1/PGC-1α pathway in DPN mice, which were all further validated in primary human Schwann cells. Additionally, AB suppressed the cross talk between Schwann cells and endothelial cells/DRG neurons in DPN mice. Collectively, our findings highlight the potential of AB for the treatment of DPN. Article Highlights The antihypertensive drug amlodipine besylate (AB) is a novel G-protein–coupled receptor 40 agonist able to ameliorate diabetic peripheral neuropathy (DPN)-like pathologies in mice. AB represses inflammation, apoptosis, and mitochondrial dysfunction in DPN mice. AB suppressed the cross talk between Schwann cells and endothelial cells/dorsal root ganglia neurons. AB shows potential in treating late-stage DPN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmlodipineDiabetic NeuropathiesAntihypertensive AgentsAnimalsMiceHumansReceptors, G-Protein-CoupledGanglia, SpinalMaleDiabetes Mellitus, ExperimentalSciatic NerveMice, Inbred C57BL

Substanzen

AmlodipineAntihypertensive AgentsReceptors, G-Protein-Coupled

Autor:innen und Institutionen

  • Jiangsu Key Laboratory of Drug Target and Drug for Degenerative Diseases, School of Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
  • Department of Burn Surgery, the First Affiliated Hospital of Naval Medical University, Shanghai, China.
  • State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Nanjing University of Chinese Medicine, Nanjing, China.

ORCID-Profile: Jiaying Wang, Shizhao Ji, Xu Shen

Förderung

  • National Natural Science Foundation of China
  • Qinglan Project of Jiangsu Province of China
  • Innovation Projects of State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture
  • Shanghai Rising-Star Program
  • Major Program of the Natural Science Foundation of the Jiangsu Higher Education Institutions of China
  • Program of Shanghai Academic Research Leader

Zitieren

APA

Wei, Y., Huang, Y., Huang, R., Ruan, Y., Feng, T., Zhou, F., Zhang, W., Lu, J., Xie, S., Yao, Y., Wang, J., Ji, S., & Shen, X. (2025). Antihypertensive Drug Amlodipine Besylate Shows Potential in Alleviating Diabetic Peripheral Neuropathy. Diabetes, 74(6), 983-997. https://doi.org/10.2337/db24-0403

Vancouver

Wei Y, Huang Y, Huang R, Ruan Y, Feng T, Zhou F, et al. Antihypertensive Drug Amlodipine Besylate Shows Potential in Alleviating Diabetic Peripheral Neuropathy. Diabetes. 2025;74(6):983-997. doi:10.2337/db24-0403

BibTeX
@article{Wei2025,
  author = {Wei, Yuxi and Huang, Yujie and Huang, Runzhi and Ruan, Yuan and Feng, Tian and Zhou, Fan and Zhang, Wei and Lu, Jianyu and Xie, Sujie and Yao, Yuntao and Wang, Jiaying and Ji, Shizhao and Shen, Xu},
  title = {Antihypertensive Drug Amlodipine Besylate Shows Potential in Alleviating Diabetic Peripheral Neuropathy},
  journal = {Diabetes},
  year = {2025},
  volume = {74},
  number = {6},
  pages = {983--997},
  doi = {10.2337/db24-0403}
}
Kostenlos starten →